Anti-Hyperglycemic Agents and New-Onset Acute Myocardial Infarction in Diabetic Patients with End-Stage Renal Disease Undergoing Dialysis

A predictive model of perioperative myocardial infarction following elective spine surgery

Myocardial infarction (MI), and its predictive factors, has been an understudied complication following spine operations. The objective was to assess the risk factors for perioperative MI in elective spine surgery patients as a retrospective case control study. Elective spine surgery patients with a perioperative MI were isolated in the NSQIP. The relationship between MI and non-MI spine patients was assessed using chi-squared and independent samples t-tests. Univariate/multivariate analyses assessed predictive factors of MI. Logistic regression with stepwise model selection was employed to create a model to predict MI occurrence. The study included 196,523 elective spine surgery patients (57.1 yrs, 48%F, 30.4 kg/m²), and 436 patients with acute MI (Spine-MI). Incidence of MI did not change from 2010 to 2016 (0.2%-0.3%, p = 0.298). Spine-MI patients underwent more fusions than patients without MI (73.6% vs 58.4%, p < 0.001), with an average of 1.03 levels fused. Spine-MI patients also had significantly more SPO (5.0% vs 1.8%, p < 0.001) and 3CO (0.9% vs 0.2%, p < 0.001), but less decompression-only procedures (26.4% vs 41.6%, p < 0.001). Spine-MI underwent more revisions (5.3% vs 2.9%, p = 0.003), had greater invasiveness scores (3.41 vs 2.73, p < 0.001) and longer operative times (211.6 vs 147.3 min, p < 0.001). Mortality rate for Spine-MI patients was 4.6% versus 0.05% (p < 0.001). Multivariate modeling for Spine-MI predictors yielded an AUC of 83.7%, and included history of diabetes, cardiac arrest and PVD, past blood transfusion, dialysis-dependence, low preoperative platelet count, superficial SSI and days from operation to discharge. A model with good predictive capacity for MI after spine surgery now exists and can aid in risk-stratification of patients, consequently improving preoperative patient counseling and optimization in the peri-operative period.

Acarbose Use and Liver Injury in Diabetic Patients With Severe Renal Insufficiency and Hepatic Diseases: A Propensity Score-Matched Cohort Study

Background: Acarbose has been deemed contraindicated in diabetic patients with chronic kidney disease (CKD) or end-stage renal disease (ESRD), but such use is not uncommon. We tested whether this concept hold true in this population with different background hepatic diseases.

Methods: All incident diabetic patients (n = 2,036,531) with stage 5 CKD/ESRD were enrolled from Taiwan between 2017 and 2013 and divided into those without chronic liver disease (CLD), with CLD but without cirrhosis, and those with cirrhosis. Among each group, acarbose users, defined as cumulative use >30 days within the preceding year, were propensity-score matched 1:2 to non-users. Our main outcome was the development of liver injury events during follow-up.

Results: Acarbose users did not exhibit an increased incidence of liver injury during follow-up compared to non-users (hazard ratio and 95% confidence interval, 1.04 [0.88–1.25], 0.97 [0.61–1.56], and 0.71 [0.33–1.54] among those without CLD, with CLD but without cirrhosis, and those with cirrhosis, respectively), after adjusting for demographic profiles, comorbidities, potentially hepatotoxic medication use, and diabetic severity.

Conclusions: The incidence of liver injury did not increase significantly among diabetic acarbose users with severe renal insufficiency than non-users, regardless of the presence or absence of chronic liver disease. Our findings support the renaissance of acarbose as a useful adjunct in diabetic patients with stage 5 and 5D chronic kidney disease.

The role of Enterobacteria, TNF-α, IL-6, and IL-10 in the development of myocardial ischemia with type 2 diabetes mellitus

This study is to observe the distribution of intestinal flora and the changes of inflammatory factors in elderly patients with myocardial ischemia complicated with type 2 diabetes mellitus. A total of 106 elderly patients with myocardial ischemia complicated with type 2 diabetes mellitus (complicated group), 106 elderly patients with simple type 2 diabetes mellitus (diabetic group), and 106 healthy elderly people (control group) were selected. The fasting blood glucose (FBG), 1-h postprandial blood glucose (1hPG), 2-h postprandial blood glucose (2hPG), 3-h postprandial blood glucose (3hPG), and hemoglobin A1c (HbA1c) in complicated group and the diabetic group were higher than those in the control group ( P < 0.05 or P < 0.01). The duration of diabetes, FBG, 3hPG, and HbA1c in the complicated group were higher than those in the diabetic group, while the 2hPG was lower than that in the diabetic group ( P < 0.05). Compared with control group, the number of Enterobacteria in the diabetic group and complicated group was increased, while the numbers of Bacteroides, Bifidobacteria, and Lactobacillus were decreased ( P < 0.05 or P < 0.01). Compared with the diabetic group, the number of Enterobacteria in complicated group was increased, while the numbers of Bacteroides, Bifidobacteria, and Lactobacillus were decreased ( P < 0.05 or P < 0.01). Compared with control group, the levels of tumor necrosis factor alpha (TNF-α), interleukin 6 (IL-6), interleukin 1 beta (IL-1β), and C-reactive protein (CRP) decreased in the diabetic group and complicated group, and the lowest in the complicated group. Conversely, the levels of interleukin 10 (IL-10) and interleukin 12 (IL-2) increased in the diabetic group and complicated group, and the highest in the complicated group ( P < 0.05 or P < 0.01). Multiple logistic regression analysis showed that the duration of diabetes, HbA1c, Enterobacteria, TNF-α, IL-6, and IL-10 were the influencing factors of myocardial ischemia complicated with type 2 diabetes mellitus ( P < 0.05 or P < 0.01). In conclusion, in the elderly patients with myocardial ischemia complicated with type 2 diabetes mellitus, the number of intestinal probiotics and the level of anti-inflammatory factors decreased, and the number of pathogenic bacteria and the level of inflammatory factors increased. Enterobacteria, TNF-α, IL-6, and IL-10 may play an important role in the development of myocardial ischemia in type 2 diabetes mellitus.

Sleep apnea and risk of vertigo: A nationwide population-based cohort study

OBJECTIVE

To investigate the risk of vertigo in patients with sleep apnea.

STUDY DESIGN

Retrospective cohort study.

METHODS

This study used data from the National Health Insurance Research Database of Taiwan, a population-based database. A total of 5,025 patients who were newly diagnosed with sleep apnea between January 1, 1997, and December 31, 2012, were identified from the Longitudinal Health Insurance Database 2000, a nationally representative database of 1 million randomly selected patients. Moreover, 20,100 patients without sleep apnea were matched at a 1:4 ratio by age, sex, socioeconomic status, and urbanization level. Patients were followed up until death or the end of the study period (December 31, 2013). The primary outcome was the occurrence of vertigo.

RESULTS

Patients with sleep apnea had a significantly higher cumulative incidence of vertigo than those without sleep apnea (P < 0.001). The adjusted Cox proportional hazard model showed that sleep apnea was significantly associated with a higher incidence of vertigo (hazard ratio, 1.71; 95% confidence interval [CI], 1.48-1.97; P < 0.001). Sensitivity and subgroup analyses were performed to adjust for confounders, including head trauma, diabetes mellitus, hypertension, stroke, and obesity. Sleep apnea was demonstrated to be an independent risk factor for vertigo.

CONCLUSION

This is the first nationwide population-based cohort study to investigate the association between sleep apnea and vertigo. The findings strongly support that sleep apnea is an independent risk factor for vertigo. Based on the study results, physicians should be aware of potential vertigo occurrence following sleep apnea.

LEVEL OF EVIDENCE

4. Laryngoscope, 128:763-768, 2017.

Association of Glycemic Status During Progression of Chronic Kidney Disease With Early Dialysis Mortality in Patients With Diabetes

OBJECTIVE

Although early trials suggested that intensive glycemic targets reduce the number of complications with diabetes, contemporary trials indicate no cardiovascular benefit and potentially higher mortality risk. As patients with advanced chronic kidney disease (CKD) transitioning to treatment with dialysis were excluded from these studies, the optimal glycemic level in this population remains uncertain. We hypothesized that glycemic status, defined by hemoglobin A_1c (HbA--_1c) and random glucose levels, in the pre-end-stage renal disease (ESRD) period is associated with higher 1-year post-ESRD mortality among patients with incident diabetes who have ESRD.

RESEARCH DESIGN AND METHODS

Among 17,819 U.S. veterans with diabetic CKD transitioning to dialysis from October 2007 to September 2011, we examined the association of mean HbA--_1c and random glucose levels averaged over the 1-year pre-ESRD transition period with mortality in the first year after dialysis initiation. All-cause mortality hazard ratios (HRs) were estimated using multivariable survival models. Secondary analyses examined cardiovascular mortality using competing risks methods.

RESULTS

HbA--_1c levels ≥8% (≥64 mmol/mol) were associated with higher mortality in the first year after dialysis initiation (reference value 6% to <7% [42-53 mmol/mol]): adjusted HRs [aHRs] 1.19 [95% CI 1.07-1.32] and 1.48 (1.31-1.67) for HbA--_1c 8% to <9% [64-75 mmol/mol] and ≥9% [≥75 mmol/mol], respectively). Random glucose levels ≥200 mg/dL were associated with higher mortality (reference value 100 to <125 mg/dL): aHR 1.34 [95% CI 1.20-1.49]). Cumulative incidence curves showed that incrementally higher mean HbA--_1c and random glucose levels were associated with increasingly higher cardiovascular mortality.

CONCLUSIONS

In patients with diabetes and CKD transitioning to dialysis, higher mean HbA--_1c and random glucose levels during the pre-ESRD prelude period were associated with higher 1-year post-ESRD mortality. Clinical trials are warranted to examine whether modulating glycemic status improves survival in this population.